# How to Use Modified Cells to Produce Insulin-Regulating Proteins in the Body

> A method for taking a patient's own cells, modifying them with DNA to produce GLP-1, and putting them back into the body to treat metabolic conditions.

- **Patent:** US 6531124
- **Original title:** In vivo production and delivery of insulinotropin for gene therapy
- **Owner:** Transkaryotic Therapies Inc
- **Granted:** 2003
- **Status:** Public domain (expired)
- **Times cited:** 2
- **Field:** biotech, pharmaceutical

## What it does

This patent describes a gene therapy approach where a patient's own somatic cells (like skin or blood cells) are removed and modified in a lab. Scientists insert a DNA construct that carries instructions for the cell to produce a specific protein, specifically GLP-1 (glucagon-like peptide 1) or its derivatives. These modified cells are then grown into a clonal strain, which means they are multiplied to create a large, consistent population. Finally, these cells are reintroduced into the patient's body, where they act as a living factory to continuously produce the desired protein.

## What it does NOT cover

- Does not cover direct injection of synthetic GLP-1 drugs like semaglutide or liraglutide.
- Does not cover viral-vector gene therapy where DNA is delivered directly into the body without cell removal.
- Does not cover the use of embryonic stem cells or germline cells.
- Does not cover the production of proteins other than GLP-1 or EPO.

## The clever bit

The innovation lies in using the patient's own primary cells to create a stable, clonal cell line that can be expanded in the lab before being returned to the body, effectively turning the patient into their own drug-manufacturing plant.

## Real-world examples

1. Experimental ex-vivo gene therapy for metabolic disorders
2. Autologous cell-based protein delivery systems

## Why it matters

This patent represents an early effort to turn the patient's own cells into a therapeutic delivery system, moving away from the need for frequent injections of synthetic hormones. While the specific approach of ex-vivo cell transplantation for GLP-1 has faced significant hurdles compared to modern injectable GLP-1 agonists, it highlights the foundational research into personalized medicine and cell-based therapies that continue to influence current biotech development.

## Frequently asked questions

### What does How to Use Modified Cells to Produce Insulin-Regulating Proteins in the Body cover?

A method for taking a patient's own cells, modifying them with DNA to produce GLP-1, and putting them back into the body to treat metabolic conditions.

### Who owns patent US 6531124?

Transkaryotic Therapies Inc owns this patent, granted in 2003.

### When does this patent expire?

This patent has expired and is now in the public domain — anyone can use the invention freely.

### What is patent US 6531124 cited by?

This patent has been cited by 2 later patents that build on its ideas.

### What problem does this patent solve?

This patent represents an early effort to turn the patient's own cells into a therapeutic delivery system, moving away from the need for frequent injections of synthetic hormones. While the specific approach of ex-vivo cell transplantation for GLP-1 has faced significant hurdles compared to modern injectable GLP-1 agonists, it highlights the foundational research into personalized medicine and cell-based therapies that continue to influence current biotech development.

### What does this patent NOT cover?

Does not cover direct injection of synthetic GLP-1 drugs like semaglutide or liraglutide.

**Full plain-English explainer:** https://patentbrief.org/patent/us/6531124/xolair-omalizumab

**Original patent:** https://patents.google.com/patent/US6531124

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._